The dipeptidyl peptidase-1 (DPP1) inhibitor brensocatib became the first licensed therapy for bronchiectasis in the USA and Europe in 2025,1 based on the phase 3 ASPEN trial showing an approximate 20% reduction in exacerbations and slower FEV1 decline with a 25 mg dose.2 Other DPP1 inhibitors, verducatib and HSK31858, showed 30% and 60% exacerbation reductions in phase 2 trials, respectively.3,4 The primary results and scientific background of DPP1 inhibitor therapy have been discussed extensively.
The Lancet Respiratory Medicine published a clinical update in Critical Care on 13 Mar 2026. The item focuses on Ten unanswered questions about dipeptidyl peptidase-1 inhibition in bronchiectasis. Open the detail page to review the full original feed content.